ArticleClinical rheumatology2025
IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectivesThis study aimed to explore the clinical characteristics, treatment, and prognosis of IgG4-related disease (IgG4-RD) patients with comorbid autoimmune diseases (AIDs).
methodA total of 879 IgG4-RD patients treatment-naïve at baseline from Peking Union Medical College Hospital were retrospectively included in this study. IgG4-RD patients with comorbid AIDs were classified into the AID-positive (AID-Pos) group, while those without AIDs were classified into the AID-negative (AID-Neg) group. Additionally, AIDs were classified as systemic or organ-specific subgroups. The clinical features, laboratory findings, treatment regimens, and long-term prognosis were compared among the AID-Pos and AID-Neg groups, and the characteristics of AIDs were also explored.
resultsAID prevalence in IgG4-RD was 9.67% (85/879), with systemic (n = 47; 55.3%) and organ-specific (n = 38; 44.7%) subtypes. Common AIDs included vitiligo (n = 15; 17.6%), systemic vasculitis (n = 12; 14.1%), psoriasis (n = 12; 14.1%), Hashimoto's thyroiditis (n = 11; 12.9%), and rheumatoid arthritis (n = 10; 11.8%). Most preceded/synchronized with IgG4-RD; 88.2% had a single AID. All groups showed a median of 3 involved organs, but AID-Neg had more multi-organ involvement. AID-Pos had lower IgG4 levels, while systemic AIDs showed higher ESR and IgG1. Treatment and prognosis did not differ between groups.
conclusionsIgG4-RD patients can complicate with other AIDs. Compared with the AID-Neg group, IgG4-RD patients with comorbid AIDs contained a lower proportion of patients with multi-organ involvement, and their patients have lower serum IgG4 levels. The treatment and prognosis were similar between the two groups. Key Points • IgG4-related disease (IgG4-RD) can complicate with autoimmune diseases (AIDs). The relationship between IgG4-RD and AID is yet to be fully elucidated. • 9.67% of IgG4-RD patients (85/879) had comorbid AIDs. AID-positive patients showed lower IgG4, and patients with systemic AIDs showed higher ESR and IgG1. • IgG4-RD and AIDs are not entirely contrary in the diagnosis of IgG4-RD.
Indexed as
Identifiers
41123771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.